Skip to main content
. 2022 Jun 17;42(6):1137–1150. doi: 10.1007/s10875-022-01296-4

Table 2.

Characteristics between responder and non-/weak responder

Responder (n = 18) Non-/weak responder (n = 5) P
Gender (male) 17% 0% 0.999
Autoimmunity 17% 80% 0.017
Malignancy 17% 50% 0.210
Age 48 ± 20 50 ± 10 0.790
Baseline values prior to initiation of IgG replacement
  IgG 671 ± 240 228 ± 119  < 0.0001
  IgM 86 ± 111 241 ± 354 0.215
  IgA 110 ± 78 47 ± 28 0.001
  IgG1 443 ± 148 99 ± 86 0.010
  IgG2 163 ± 105 43 ± 22 0.022
  IgG3 34 ± 23 29 ± 10 0.110
  IgG4 14 ± 15 6 ± 7.2 0.155
Laboratory data (%)
  CD3 72 ± 7 78 ± 12 0.177
  CD4 66 ± 10 53 ± 20 0.228
  CD8 20 ± 8 15 ± 12 0.118
  CD8 naive 36 ± 21 27 ± 18 0.021
  CD8 CM 11 ± 8 9 ± 10 0.465
  CD8 EM 26 ± 12 30 ± 12 0.047
  CD8 EMRA 24 ± 20 32 ± 14 0.126
  CD19 8 ± 5 5 ± 3 0.023
  CD19 CD27+ IgDIgM 23 ± 12 9 ± 2 0.004
  CD19 CD27 CD21low 38 ± 27 55 ± 26 0.166
  cTfh (PD-1+) cells 2.5 ± 1.4 3.3 ± 3 0.555
  cTfh (PD-1-) cells 8.5 ± 2.6 9.8 ± 3.1 0.425

Abbreviations: CM central memory, EM effector memory, EMRA CD45RA positive EM, cTfh circulating T follicular helper cells. P-values marked with bold indicate statistically significant p-values